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Abstract
Background: Potential benefits of subglottic secretion suction for preventing ventilator-associated pneumonia
(VAP) are not fully understood.
Methods: We searched Cochrane Central, PubMed, and EMBASE up to March 2016 to identify randomized controlled
trials (RCTs) that compared subglottic secretion suction versus non-subglottic secretion suction in adults with mechanical
ventilation. Meta-analysis was conducted using Revman 5.3, trial sequential analysis (TSA) 0.9 and STATA 12.0. The
primary outcome was incidence of VAP. The Grading of Recommendations Assessment, Development, and Evaluation
(GRADE) was used to evaluate the level of evidence.
Results: Twenty RCTs (N = 3544) were identified. Subglottic secretion suction was associated with reduction of VAP
incidence in four high quality trials (relative risk (RR) 0.54, 95 % confidence interval (CI) 0.40–0.74; p < 0.00001) and in all
trials (RR = 0.55, 95 % CI 0.48– 0.63; p < 0.00001). Sensitivity analyses did not show differences in the pooled results.
Additionally, the results of the above-mentioned analyses were confirmed in TSA. GRADE level was high. Subglottic
secretion suction significantly reduced incidence of early onset VAP, gram-positive or gram-negative bacteria causing
VAP, and duration of mechanical ventilation. It delayed the time-to-onset of VAP. However, no significant differences in
late onset VAP, intensive care unit (ICU) mortality, hospital mortality, or ICU length of stay were found.
Conclusions: Subglottic secretion suction decreased VAP incidence and duration of mechanical ventilation and
delayed VAP onset. However, subglottic secretion suction did not reduce mortality and length of ICU stay.
Subglottic secretion suction is recommended for preventing VAP and for reducing ventilation length, especially
in the population at high risk of early onset VAP.
Trial registration: A protocol of this meta-analysis has been registered on PROSPERO (registration number:
CRD42015015715); registered on 5 January 2015.
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Background
Ventilator-associated pneumonia (VAP) is a common
clinical issue for patients receiving mechanical ventila-
tion in the intensive care unit (ICU) [1]. The incidence
of VAP accounts for 9 % to 27 % endotracheal intubated
patients, whereas VAP has a mortality rate ranging from
25 % to 50 % [2–4]. VAP increased ICU and hospital
length of stay, antibiotic consumption, and healthcare
cost [5–8]. The primary mechanism of VAP is the
microaspiration of the accumulated secretions around
the endotracheal tube cuff. Preventive measures for
microaspiration and VAP include continuous control of
tracheal cuff pressure, conical cuff shape, and subglottic
secretion suctioning (SSS).
SSS has been recommended in several guidelines to pre-
vent the occurrence of VAP [9, 10]. Previous meta-analyses
reported that SSS was associated with a lower rate of VAP
[11–16]. However, many ICUs did not use SSS as a part of
the VAP bundle [17]. Although about 55 % of hospitals in
the US routinely used SSS in 2013 [18], European consen-
sus did not recommend SSS for VAP prevention [19]. The
prevention of VAP by SSS is not fully proven based on
current evidence. The effect of SSS on early- or late-onset
VAP, duration of mechanical ventilation, ICU length of
stay, and mortality is controversial [16]. The need for fu-
ture randomized controlled trials (RCTs) is still advo-
cated [15, 16]. Six RCTs [17, 20–24] involving new
evidence on this topic have been published recently.
Therefore, we conducted an updated meta-analysis of
RCTs to evaluate the effect of SSS on VAP prevention.
Trial sequential analysis (TSA) was used to determine
whether the currently evidence was robust and conclusive.
Methods
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) were used to report this
systematic review and meta-analysis [25]. A protocol for
this meta-analysis has been registered on PROSPERO
(http://www.crd.york.ac.uk/prospero), and the registration
number is CRD42015015715.
Eligibility criteria
The inclusion criteria were as follows: 1) patients re-
ceived mechanical ventilator (≥48 h); 2) intervention was
SSS regardless of continuous or intermittent SSS; 3) the
control was the non-subglottic secretion suctioning
group; 4) the incidence of VAP was reported; and 5) the
study design was RCT. The exclusion criteria were pa-
tients younger than 18 years and repeated data.
Search strategy
A literature search of Cochrane Central (March 2016),
PubMed (1950 to March 2016), and EMBASE (1980 to
March 2016) was undertaken to identify trials according
to Cochrane Collaboration methodology. The search
terms used were “ventilator-associated pneumonia” with
“subglottic secretion” or “subglottic drainage” or “sub-
glottic suctioning” or “glottic” and “randomized” or
“randomised”. No language restriction was applied. We
also hand-searched the reference lists of review articles
and conference proceedings.
Study selection
Two independent reviewers (ZM and LG) conducted the
study selection. Disagreements between the two reviewers
were resolved in meetings or adjudicated by a third
reviewer (GW).
Data extraction
For each included study, data extraction was performed
independently by two reviewers using a standard form.
The following data on study characteristics were collected:
year of publication, the study type, number of patients,
patient characteristics, method of SSS, definition of
VAP, incidence of VAP, length of ICU stay, duration of
mechanical ventilation (MV), mortality, airway secre-
tion bacteria detection, and details of the outcomes.
The quality of included studies was assessed by the
Cochrane risk of bias tool [26]. Trials with low risk of
bias in all items were evaluated as high-quality studies.
Grading the quality of evidence
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) methodology was used to assess
the quality of evidence classified as high, moderate, low,
or very low. The judgments were based on risk of bias,
inconsistency, indirectness, imprecision, and publication
bias. GRADE Pro-version 3.6 software was used.
Statistical analysis
Dichotomous variables were presented as relative risks
(RRs), and continuous variables were presented as mean
difference (MD), both with 95 % confidence intervals
(CIs). Heterogeneity across studies was evaluated by
visual inspection of the forest plot, along with quantifi-
cation using the I2 statistic. An I2 > 50 % was considered
as significant heterogeneity. A fixed-effects model was
used in the meta-analysis unless significant heterogeneity
among studies was present. The random-effects model
of DerSimonian and Laird [27] was used regardless of
heterogeneity. Statistical analysis was performed with
Review Manager 5.1 software (Cochrane Collaboration,
Oxford, UK) for outcome measures. A p value <0.05 was
considered statistically significant. We assessed publica-
tion bias by visually inspecting a funnel plot. The Begg
and Egger tests were also conducted using STATA 12.0.
For the primary result, predefined subgroup analyses
were performed as the high-quality subgroup, and the
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primary result from high-quality trials was emphasized.
Sensitivity analysis for primary results were conducted
by excluding trials with multiple manipulations, continuous
versus intermittent suction, appropriate randomization,
allocation concealment, assessment blinding, and partici-
pants numbering more than 100. We also performed sensi-
tivity analyses using an invasive diagnosis of VAP in all
outcomes.
The second outcomes were incidence of early- or late-
onset VAP, gram-positive or gram-negative bacteria causing
VAP, ICU or hospital mortality, time-to-onset of VAP,
duration of mechanical ventilation, ICU or hospital length
of stays, and incidence of tracheotomy or reintubation.
Trial sequential analysis
TSA, which is similar to an interim trial analysis in a
single trial, was conducted to obtain the primary result.
Cumulative meta-analysis that is updated with new studies
may result in false positive results (type I error) because of
an increased risk of random error from sparse data and
repeated significance testing [28]. TSA can control the p
value and widen the confidence intervals [29]. TSA com-
bined concepts and rationale as follows: an estimation of
the required information size and trial sequential moni-
toring boundaries. If the cumulative Z curve enters the
futility area or crosses the trial sequential monitoring
boundary, the anticipated intervention effect may reach
a sufficient level of evidence, and further trials will not
be necessary. If the Z curve does not cross any of the
boundaries or reach the required information size, evi-
dence is insufficient for drawing a conclusion.
We calculated the required information size based on
a relative risk reduction of 20 % in incidence of VAP.
The type I error (α) and power (1 – β) were set as 0.05
and 0.80, respectively. The control event rates were cal-
culated from the non-subglottic secretion suctioning
group. The TSA was conducted with the use of TSA
version 0.9 beta software (http://www.ctu.dk/tsa).
Results
Trial selection
A total of 11,756 potentially relevant articles were used.
We excluded duplicate studies, non-relevant topic arti-
cles, non-RCTs, and non-suitable intervention studies.
Twenty studies reported that 3544 patients were included
in this meta-analysis (Fig. 1) [17, 20–24, 30–43].
Trials characteristics
The main characteristics of the selected studies are sum-
marized in Table 1. These studies were reported between
1992 and 2016, and a total of 3544 patients were in-
cluded. Fourteen studies were published in English
[17, 20, 21, 23, 24, 30–32, 34–36, 38, 39, 42], five in
Chinese [22, 33, 37, 40, 41], and one in Persian [43].
One abstract was included [24].
Risk of bias assessment
Risk of bias is summarized in Fig. 2. Twelve studies re-
ported and adequate randomized sequence generated
[17, 20–22, 34–36, 38–42], five studies reported appro-
priate allocation concealment [17, 20, 34, 39, 42], and
seven studies reported blinding of outcome assessments
[17, 23, 31, 34, 35, 38, 42]. Four studies were high-
quality studies with low risk of bias in all items (Fig. 2)
[17, 20, 34, 42].
Primary outcome: incidence of VAP
Four high-quality studies with 901 participants were
included in the analysis of VAP incidence (Fig. 3)
[17, 20, 34, 42], thereby suggesting an RR of 0.54
(95 % CI 0.40–0.74; p < 0.00001; p for heterogeneity =
0.39, I2 = 0 %) for SSS versus non-SSS. Absolute risk re-
duction (ARR) was 0.0953. The number needed to treat
(NNT) was 10.49. TSA showed that the cumulative Z
curves crossed both the conventional boundary and the
trial sequential monitoring boundary. Thus, further trials
were unlikely to change the conclusion (Fig. 3, Table 2).
Twenty studies totalling 3544 patients provided data on
incidence of VAP despite a risk of bias. Overall, subglottic
secretion suction significantly prevented the incidence of
VAP (RR = 0.55, 95 % CI 0.48–0.63; p < 0.00001; p for
heterogeneity = 0.85, I2 = 0 %) (Fig. 1). TSA showed that
the cumulative Z curves crossed both the conventional
and the trial sequential monitoring boundaries and
reached the significant area, which led us to draw a
conclusion. Thus, it is unlikely that further trials will
change the conclusion and are not necessary (Fig. 4).
Sensitivity analyses were performed to evaluate only
including trials using invasive diagnosis of VAP, the
Fig. 1 Flow chart of the trial selection. RCT randomized controlled trial
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Table 1 Characteristics of included studies (Continued)
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significant quantitative
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Table 1 Characteristics of included studies (Continued)
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Fig. 2 Risk of bias table
Fig. 3 Effect of subglottic secretion suction on preventing ventilator-associated pneumonia in four high-quality trials. a Forest plot comparing
subglottic secretion suction (SSS) and non-SSS on incidence of ventilator-associated pneumonia. b Trial sequential analysis for incidence of
ventilator-associated pneumonia with control arm event proportion of 21.2 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and
I2 = 0 %. The required information size was calculated as 2729. Z curve has across-trial sequential monitoring boundary for benefit. Risk of bias:
A random sequence generation (selection bias), B allocation concealment (selection bias), C blinding of outcome assessment (detection bias),
D incomplete outcome data (attrition bias), E selective reporting (reporting bias), F other bias; CI confidence interval, M-H Mantel-Haenszel
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Table 2 The GRADE evidence quality for primary outcome, sensitivity analysis, and secondary outcomes
Categaries Outcomes Number of studies Risk ratio or mean
difference (95 % CI)
P P for heterogeneity I2 (%) Quality
Primary outcome Sensitivity analysis VAP high-quality trials 4 [17, 20, 34, 42] 0.54 (0.40, 0.74) <0.00001 0.39 0 Moderatec
VAP total trials 20 [17, 20–24, 30–43] 0.55 (0.48, 0.63) <0.00001 0.85 0 Higha
VAP invasive diagnosis 13 [17, 20, 22, 30, 31, 33, 35–40, 42] 0.55 (0.47, 0.65) <0.00001 0.60 0 Higha
VAP excluding trials with multiple
manipulations
16 [17, 22–24, 30–34, 36–43] 0.55 (0.48, 0.65) <0.00001 0.97 0 Higha
VAP randomization 12 [17, 20–22, 34, 35, 37–42] 0.56 (0.47, 0.66) <0.00001 0.37 7 Higha
VAP allocation concealment 5 [17, 20, 34, 39, 42] 0.56 (0.42, 0.74) <0.00001 0.53 0 Moderatec
VAP assessment blinded 8 [17, 20, 23, 31, 34, 35, 38, 42] 0.53(0.42, 0.66) <0.00001 0.34 11 Moderatec
VAP participants more than 100 10 [17, 21, 22, 30–32, 34, 38, 39, 42] 0.54(0.45, 0.65) <0.00001 0.55 0 Higha
VAP intermittent SSS 9 [21–23, 30, 34, 37, 38, 42, 43] 0.52 (0.43, 0.64) <0.00001 0.25 22 Higha
VAP continuous SSS 11 [20, 22, 24, 31–33, 35, 36, 39–41] 0.61(0.5, 0.73) <0.00001 0.91 0 Higha
Secondary outcomes Early-onset VAP 9 [22–24, 33, 36–38, 42, 43] 0.34 (0.25, 0.47) <0.00001 0.84 0 Moderatec
Late-onset VAP 5 [22, 33, 36, 38, 42] 0.80 (0.62, 1.02) 0.07 0.17 35 Moderatec
Gram-negative bacteria 6 [31, 32, 38–40, 42] 0.58(0.43, 0.77) 0.0002 0.69 0 Moderatec
Gram-positive bacteria 5 [31, 33, 38, 40, 42] 0.32 (0.17, 0.61) 0.006 0.61 0 Lowb
ICU mortality 8 [17, 20, 30, 31, 38, 39, 41, 42] 0.98(0.85, 1.13) 0.77 0.88 0 High
Hospital mortality 7 [17, 21, 32, 34, 37, 40, 42] 0.92 (0.80, 1.05) 0.20 0.82 0 High
Time-to-onset of VAPg 7 [30–33, 37, 40, 41] 3.92 (2.56, 5.27) <0.00001 <0.00001 92 Moderated
Duration of MVg 6 [20, 32, 34, 37, 38, 41] −1.17 (–2.28, –0.06) 0.006 0.06 54 Moderated
ICU length of stayg 4 [32, 34, 38, 41] 37 −1.64 (–3.95, 0.66) 0.16 0.001 81 Moderated
Hospital length of stay 3 [32, 34] −1.44 (–3.93, 1.04) 0.25 0.99 0 High
Reintubation 4 [20, 32, 39, 42] 0.77 (0.45, 1.32) 0.34 0.19 38 Lowb
Tracheotomyg 3 [32, 38, 42] 1.14 (0.75, 1.72) 0.55 0.79 54 Lowb
CI confidence interval, GRADE Grading of Recommendations Assessment, Development, and Evaluation, ICU intensive care unit, MV mechanical ventilation, NA not available, SSS subglottic secretion suctioning,
VAP ventilator-associated pneumonia
aTotal number of events is more than 300
bTotal number of events is less than 100
cTotal number of events is less than 300
dI2 > 50 %
eThe total number of patients is relatively small (<500)











influence of the intervention types, risk of bias, and
sample size on the combined estimates (Table 2). Some
confounding interventions, such as polyurethane cuff
[20, 38], continuous control of cuff pressure [21], and
semi-recumbent position [35] existed in some included
trials. The sensitivity analysis excluded these trials, which
used other confounding interventions [20, 21, 35, 38]. The
result of sensitivity analysis was stable (Table 2). Addition-
ally, TSA of sensitivity analyses were conducted to confirm
the significant results (Fig. 5).
Secondary outcomes
SSS was significantly associated with a reduction in the
incidence of early-onset VAP, gram-positive or gram-
negative bacteria causing VAP, and duration of mechanical
ventilation. SSS also delayed the time-to-onset of VAP.
However, no significant difference was detected between
SSS and non-SSS in terms of late-onset VAP, ICU mor-
tality, hospital mortality, ICU length of stay, incidence
of tracheotomy, or reintubation (Table 2). Sensitivity
analyses using an invasive diagnosis of VAP in all second-
ary outcomes did not show additional significant results
(Additional file 1: Table S1).
GRADE
The GRADE level of evidence is high for VAP inci-
dence, hospital mortality, and hospital length of stay,
but moderate for early-onset VAP, gram-negative bac-
teria causing VAP, ICU mortality, time to achieve VAP,
and duration of mechanical ventilation and ICU stay.
Table 2 shows the GRADE evidence profiles. The main
reasons for a deceasing level were inconsistency and
limited sample size.
Fig. 4 Effect of subglottic secretion suction on preventing ventilator-associated pneumonia in all included trials. a Forest plot comparing subglottic
secretion suction (SSS) and non-SSS on incidence of ventilator-associated pneumonia. b Trial sequential analysis for incidence of ventilator-associated
pneumonia with control arm event proportion of 22.5 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and I2 = 0 %. The required
information size was calculated as 2504. Z curve has across-trial sequential monitoring boundary for benefit and required information size. Risk of bias:
A random sequence generation (selection bias), B allocation concealment (selection bias), C blinding of outcome assessment (detection bias), D incomplete
outcome data (attrition bias), E selective reporting (reporting bias), F other bias; CI confidence interval, M-H Mantel-Haenszel
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Fig. 5 (See legend on next page.)
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Publication bias
For the meta-analysis of VAP including all trials no sig-
nificant publication bias was observed by inspection of
the funnel plot (Additional file 2: Figure S1). The Begg
test and Egger test showed that no significant publication
bias was detected (p = 0.770 and p = 0.051, respectively).
Discussion
Our systematic review and meta-analysis found that SSS
significantly reduced the incidence of VAP both in high-
quality trials and in all included trials. The beneficial evi-
dence was consistent in all sensitivity analysis and was
validated by TSA. Meanwhile, SSS further reduced early-
onset VAP, incidence of bacteria detection in airway se-
cretion, duration of MV, and delayed time-to-onset of
VAP. However, SSS did not shorten length of ICU stay,
or improve ICU or hospital mortality regardless of the
clinical diagnosis or invasive diagnosis of VAP.
Several previous meta-analyses have reported on the
same topic, as presented in Additional file 3 (Table S2)
[11–16]. Differences between the present meta-analysis
and the previous ones are as follows. First, our meta-
analysis included three additional trials that were pub-
lished recently, and these were not included in previous
meta-analyses. As the latest and most comprehensively
updated meta-analysis, the present study further reinforces
the earlier results of previous meta-analyses. Second, we
registered the protocol of this study on PROSPERO. A reg-
istered protocol may increase the transparency and quality
of meta-analysis. Third, TSA was further applied to esti-
mate the effect more conservatively. We also used TSA of
subgroup analysis and sensitivity analysis to confirm the
conclusion. Fourth, the present study adds outcome data
to the current body of evidence as follows: SSS may pre-
vent early-onset VAP, reduce incidence of bacteria detec-
tion, prolong time-to-onset of VAP, and reduce duration of
MV. Last, but not least, we give the evidence body level
using the GRADE approach. Thus, the conclusions of this
study can be clinically used and transferred to guidelines.
The present meta-analysis showed that SSS may sig-
nificantly reduce the incidence of VAP. We calculated
the ARR (0.0953) and NNT (10.49). This value of ARR
(0.0953) meant that SSS can reduce 9.53 % of the abso-
lute rate of VAP. NNT (10.49) means that for every 11
patients with SSS, one VAP was prevented. Additionally,
we tried to answer a second question whether or not fu-
ture research is needed to confirm this conclusion. Two
current effective approaches, namely TSA and GRADE,
were used.
Sensitivity analyses found that both intermittent and
continuous suction can prevent VAP, with no significant
difference between subgroups. It is difficult to determine
which approach is appropriate because the current evi-
dence is limited. Berra et al. reported that continuous
suction was associated with widespread injury to the app-
tracheal mucosa/submucosa [44]. Thus, an intermittent
approach may be beneficial for efficacy and safety. How-
ever, tracheal damage with subglottic secretion drainage is
observed in animal studies but not in human data. Addi-
tionally, no side effects, such as tracheal damage, have
been reported despite the large number of patients with
SSS worldwide. Moreover, the trials [11, 13–15, 44] on
SSS-related complications are rare, and further trials com-
paring intermittent and continuous suction are needed.
The present study suggested that SSS may significantly
prevent early-onset VAP, but not late-onset VAP. The at-
tributable mortality of late-onset VAP is higher than that
of early-onset VAP, which weakens the impact of SSS on
mortality from VAP. Dezfulian et al. suggested that SSS
could prevent early-onset VAP in their meta-analysis,
but late-onset VAP was not addressed in their study
[11]. A meta-analysis by Wang et al. reported that SSS
did not significantly reduce incidence of late-onset VAP
based on three trials (591 patients) [15]. In the present
meta-analysis, we included five trials (963 patients), and
(See figure on previous page.)
Fig. 5 Trial sequential analysis for sensitivity analysis of incidence of ventilator-associated pneumonia. In (a–h) TSA plots, all Z curves have crossed
the trial sequential monitoring boundary for benefit. a Trial sequential analysis in 12 appropriate randomized trials with control arm event proportion
of 20.5 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and I2 = 7 %. The required information size was calculated as 2811. b Trial
sequential analysis in five appropriate allocation concealment trials with control arm event proportion of 14.2 %, relative risk reduction of 20 %, α of
5 % (two sided), β of 20 %, and I2 = 0 %. The required information size was calculated as 4339. c Trial sequential analysis in eight appropriate assessment
blinded trials with control arm event proportion of 24.5 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and I2 = 11 %. The required
information size was calculated as 2248. d Trial sequential analysis in 10 trials including over 100 participants with control arm event proportion of 18.0 %,
relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and I2 = 0 %. The required information size was calculated as 3289. e Trial sequential analysis
in nine intermittent suction trials with control arm event proportion of 26.7 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %,
and I2 = 22 %. The required information size was calculated as 2010. f Trial sequential analysis in 11 continuous suction trials with control arm
event proportion of 22.3 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and I2 = 22 %. The required information size was
calculated as 2532. g Trial sequential analysis in 13 trials with control arm event proportion of 23.0 %, relative risk reduction of 20 %, α of 5 %
(two sided), β of 20 %, and I2 = 0 %. The required information size was calculated as 2436. h Trial sequential analysis in 16 trials excluding multiple
manipulations studies with control arm event proportion of 16.1 %, relative risk reduction of 20 %, α of 5 % (two sided), β of 20 %, and I2 = 0 %. The
required information size was calculated as 2547. SSS, subglottic secretion suctioning
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no significant difference was suggested. Based on the
results, SSS may be suitable for patients with high risk
of early-onset VAP.
Our meta-analysis also suggested that SSS can reduce
incidence of bacteria detection, including both gram-
negative bacteria and gram-positive bacteria causing
VAP. This finding, which was not analysed in previous
meta-analyses, supports the pathogenesis of VAP that
leakage of fluid with bacteria passes the tracheal tube
cuff toward the lungs [45–48]. Our meta-analysis also
found that SSS significantly delayed the time-to-onset of
VAP. According to this finding, SSS may greatly reduce
incidence of VAP in patients who may have undergone
early tracheal extubation. Our meta-analysis suggested that
SSS can reduce the duration of MV. Interaction between
the duration of MV and VAP may exist. Observational
studies showed that VAP, especially early-onset VAP [49],
was associated with an increased duration of MV [50].
However, most RCTs did not show a significant reduction
of MV duration, whereas VAP was effectively prevented.
Sample size was amplified through meta-analysis. Thus,
data synthesis may introduce a different result.
This study failed to show that SSS could significantly
reduce ICU and hospital mortality, as well as the length
of ICU stay. There may be several reasons for this. Firstly,
these outcomes may have many influencing factors or con-
founding bias [40, 45–48]. Secondly, VAP was associated
with a 20–30 % higher risk increase of mortality [2, 42]
than for non-VAP patients; thus, an ARR (0.0953) of VAP
in this study may reduce the ICU mortality by 1.9–2.9 %.
As the mortality of the control group was 25.6 % (as in our
study), a very large sample size (at least 1940–4519 in each
arm) would be needed to reach a significant result for ICU
mortality [42]. Thirdly, the large database epidemiologic
study of Rello et al. [3] also suggested that VAP-preventing
strategies may not improve the survival rate, but they may
provide other important advantages to patients, their
families, and hospital systems.
SSS also has some disadvantages. The first disadvantage
is the narrower inner lumen of the endotracheal tubes
which may increase the airway resistance. Secondly, endo-
tracheal tubes with SSS would result in unjustified
incremental costs [51]. This limits the use of SSS. A pro-
spective observational study showed that only 41.5 % of all
intubated patients used SSS [52].
A major strength of this study is the application of
Cochrane methodology and complying with the PRISMA
guidelines. Moreover, our study protocol was registered in
PROSPERO. To increase the robustness of this meta-
analysis, TSA was conducted to evaluate the risk of ran-
dom error and repetitive testing. Sensitivity analyses based
on various selection criteria all obtained a significant re-
sult both in traditional meta-analysis and in TSA, which
robustly supported our primary finding. Moreover, the
GRADE approach was performed to give the level of
evidence.
Our meta-analysis also has limitations. Firstly, the in-
cluded RCTs in this meta-analysis were performed in
different patient groups and various clinical settings.
Therefore, the risk of introducing potential heterogeneity
is present, although the detected heterogeneity is not
significant. Secondly, because SSS is an obvious clinical
manipulation, it could not be blinded for physicians and
nurses; this may lead to unavoidable performance bias.
Thirdly, confounding interventions, such as polyurethane,
continuous control of cuff pressure, and semi-recumbent
position, existed in some included trials. Therefore, we
performed a sensitivity analysis excluding these trials
which used other confounding interventions. Fortunately,
the result of sensitivity analysis was stable. Fourthly, data
on cost-effectiveness of SSS was unavailable in our meta-
analysis. The main problem with SSS is the fact that, in
some countries, a large number of patients are intubated
before ICU admission with a tracheal tube without an
SSS channel. Although previous retrospective studies
suggested that SSS was cost-effective [53, 54], no RCT
has conducted cost-effectiveness analysis. Thus, the wide-
spread use of SSS is limited, and RCTs with cost-
effectiveness analysis may be needed.
Conclusions
This meta-analysis suggests that SSS significantly reduced
the incidence of VAP, early-onset VAP, gram-positive or
gram-negative bacteria causing VAP, and duration of mech-
anical ventilation. SSS delayed the time-to-onset of VAP.
However, SSS did not show a significant difference in terms
of late-onset VAP, ICU mortality, hospital mortality, ICU
length of stay, incidence of tracheotomy, or reintubation. In
summary, SSS is recommended to prevent VAP and to re-
duce ventilation length, especially in the population at high
risk of early-onset VAP.
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